Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Uesaka K, et al. Among authors: sata n. Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. Lancet. 2016. PMID: 27265347 Clinical Trial.
The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery.
Sata N, Kurashina K, Nagai H, Nagakawa T, Ishikawa O, Ohta T, Oka M, Kinoshita H, Kimura W, Shimada H, Tanaka M, Nakao A, Hirata K, Yasuda H. Sata N, et al. J Hepatobiliary Pancreat Surg. 2009;16(4):485-92. doi: 10.1007/s00534-009-0077-7. Epub 2009 Mar 31. J Hepatobiliary Pancreat Surg. 2009. PMID: 19333537
Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer.
Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Hirohashi S, Yamada T. Matsubara J, et al. Among authors: sata n. Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):160-71. doi: 10.1158/1055-9965.EPI-10-0397. Epub 2010 Dec 8. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21148121
Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation.
Honda K, Okusaka T, Felix K, Nakamori S, Sata N, Nagai H, Ioka T, Tsuchida A, Shimahara T, Shimahara M, Yasunami Y, Kuwabara H, Sakuma T, Otsuka Y, Ota N, Shitashige M, Kosuge T, Büchler MW, Yamada T. Honda K, et al. Among authors: sata n. PLoS One. 2012;7(10):e46908. doi: 10.1371/journal.pone.0046908. Epub 2012 Oct 8. PLoS One. 2012. PMID: 23056525 Free PMC article.
Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Huang W, Yamada T, Tachikawa M, Terasaki T. Yoneyama T, et al. Among authors: sata n. PLoS One. 2016 Aug 31;11(8):e0161009. doi: 10.1371/journal.pone.0161009. eCollection 2016. PLoS One. 2016. PMID: 27579675 Free PMC article. Clinical Trial.
Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
Hirata Y, Kobayashi T, Nishiumi S, Yamanaka K, Nakagawa T, Fujigaki S, Iemoto T, Kobayashi M, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Yamada T, Honda K, Azuma T, Yoshida M. Hirata Y, et al. Among authors: sata n. Clin Chim Acta. 2017 May;468:98-104. doi: 10.1016/j.cca.2017.02.011. Epub 2017 Feb 16. Clin Chim Acta. 2017. PMID: 28215548
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T; JASPAC 01 Study Group. Hagiwara Y, et al. Among authors: sata n. Eur J Cancer. 2018 Apr;93:79-88. doi: 10.1016/j.ejca.2018.01.081. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29477795 Clinical Trial.
Outcomes of 1,639 hepatectomies for non-colorectal non-neuroendocrine liver metastases: a multicenter analysis.
Sano K, Yamamoto M, Mimura T, Endo I, Nakamori S, Konishi M, Miyazaki M, Wakai T, Nagino M, Kubota K, Unno M, Sata N, Yamamoto J, Yamaue H, Takada T; Japanese Society of Hepato-Biliary-Pancreatic Surgery. Sano K, et al. Among authors: sata n. J Hepatobiliary Pancreat Sci. 2018 Nov;25(11):465-475. doi: 10.1002/jhbp.587. Epub 2018 Nov 20. J Hepatobiliary Pancreat Sci. 2018. PMID: 30311741
351 results